1
|
Ibarra-Gutiérrez MT, Serrano-García N, Orozco-Ibarra M. Rotenone-Induced Model of Parkinson's Disease: Beyond Mitochondrial Complex I Inhibition. Mol Neurobiol 2023; 60:1929-1948. [PMID: 36593435 DOI: 10.1007/s12035-022-03193-8] [Citation(s) in RCA: 27] [Impact Index Per Article: 27.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2022] [Accepted: 12/23/2022] [Indexed: 01/04/2023]
Abstract
Parkinson's disease (PD) is usually diagnosed through motor symptoms that make the patient incapable of carrying out daily activities; however, numerous non-motor symptoms include olfactory disturbances, constipation, depression, excessive daytime sleepiness, and rapid eye movement at sleep; they begin years before motor symptoms. Therefore, several experimental models have been studied to reproduce several PD functional and neurochemical characteristics; however, no model mimics all the PD motor and non-motor symptoms to date, which becomes a limitation for PD study. It has become increasingly relevant to find ways to study the disease from its slowly progressive nature. The experimental models most frequently used to reproduce PD are based on administering toxic chemical compounds, which aim to imitate dopamine deficiency. The most used toxic compounds to model PD have been 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-hydroxydopamine (6-OHDA), which inhibit the complex I of the electron transport chain but have some limitations. Another toxic compound that has drawn attention recently is rotenone, the classical inhibitor of mitochondrial complex I. Rotenone triggers the progressive death of dopaminergic neurons and α-synuclein inclusions formation in rats; also, rotenone induces microtubule destabilization. This review presents information about the experimental model of PD induced by rotenone, emphasizing its molecular characteristics beyond the inhibition of mitochondrial complex I.
Collapse
Affiliation(s)
- María Teresa Ibarra-Gutiérrez
- Laboratorio de Neurobiología Molecular y Celular, Instituto Nacional de Neurología y Neurocirugía, Av. Insurgentes Sur No. 3877 Col. La Fama, Tlalpan, C.P. 14269, Ciudad de Mexico, Mexico
| | - Norma Serrano-García
- Laboratorio de Neurobiología Molecular y Celular, Instituto Nacional de Neurología y Neurocirugía, Av. Insurgentes Sur No. 3877 Col. La Fama, Tlalpan, C.P. 14269, Ciudad de Mexico, Mexico
| | - Marisol Orozco-Ibarra
- Laboratorio de Neurobiología Molecular y Celular, Instituto Nacional de Neurología y Neurocirugía, Av. Insurgentes Sur No. 3877 Col. La Fama, Tlalpan, C.P. 14269, Ciudad de Mexico, Mexico.
| |
Collapse
|
2
|
Cao Y, Li B, Ismail N, Smith K, Li T, Dai R, Deng Y. Neurotoxicity and Underlying Mechanisms of Endogenous Neurotoxins. Int J Mol Sci 2021; 22:12805. [PMID: 34884606 PMCID: PMC8657695 DOI: 10.3390/ijms222312805] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2021] [Revised: 11/09/2021] [Accepted: 11/10/2021] [Indexed: 12/16/2022] Open
Abstract
Endogenous and exogenous neurotoxins are important factors leading to neurodegenerative diseases. In the 1980s, the discovery that 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) contributes to Parkinson's disease (PD) symptoms led to new research investigations on neurotoxins. An abnormal metabolism of endogenous substances, such as condensation of bioamines with endogenous aldehydes, dopamine (DA) oxidation, and kynurenine pathway, can produce endogenous neurotoxins. Neurotoxins may damage the nervous system by inhibiting mitochondrial activity, increasing oxidative stress, increasing neuroinflammation, and up-regulating proteins related to cell death. This paper reviews the biological synthesis of various known endogenous neurotoxins and their toxic mechanisms.
Collapse
Affiliation(s)
- Yanlu Cao
- Beijing Key Laboratory for Separation and Analysis in Biomedicine and Pharmaceuticals, School of Life Science, Beijing Institute of Technology, Beijing 100081, China; (Y.C.); (T.L.); (Y.D.)
| | - Bo Li
- Beijing Key Laboratory for Separation and Analysis in Biomedicine and Pharmaceuticals, School of Life Science, Beijing Institute of Technology, Beijing 100081, China; (Y.C.); (T.L.); (Y.D.)
- Advanced Research Institute of Multidisciplinary Science, Beijing Institute of Technology, Beijing 100081, China
| | - Nafissa Ismail
- Neuroimmunology, Stress and Endocrinology (NISE) Lab, School of Psychology, Faculty of Social Science, University of Ottawa, Ottawa, ON K1N 6N5, Canada; (N.I.); (K.S.)
- Brain and Mind Research Institute, University of Ottawa, Ottawa, ON K1N 6N5, Canada
| | - Kevin Smith
- Neuroimmunology, Stress and Endocrinology (NISE) Lab, School of Psychology, Faculty of Social Science, University of Ottawa, Ottawa, ON K1N 6N5, Canada; (N.I.); (K.S.)
| | - Tianmei Li
- Beijing Key Laboratory for Separation and Analysis in Biomedicine and Pharmaceuticals, School of Life Science, Beijing Institute of Technology, Beijing 100081, China; (Y.C.); (T.L.); (Y.D.)
- Advanced Research Institute of Multidisciplinary Science, Beijing Institute of Technology, Beijing 100081, China
| | - Rongji Dai
- Beijing Key Laboratory for Separation and Analysis in Biomedicine and Pharmaceuticals, School of Life Science, Beijing Institute of Technology, Beijing 100081, China; (Y.C.); (T.L.); (Y.D.)
| | - Yulin Deng
- Beijing Key Laboratory for Separation and Analysis in Biomedicine and Pharmaceuticals, School of Life Science, Beijing Institute of Technology, Beijing 100081, China; (Y.C.); (T.L.); (Y.D.)
| |
Collapse
|
3
|
Chirkova ZV, Kabanova MV, Filimonov SI, Abramov IG, Petzer A, Hitge R, Petzer JP, Suponitsky KY. Optimization of pyrrolo[3,4-f]indole-5,7-dione and indole-5,6-dicarbonitrile derivatives as inhibitors of monoamine oxidase. Drug Dev Res 2019; 80:970-980. [PMID: 31348537 DOI: 10.1002/ddr.21576] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2019] [Revised: 06/24/2019] [Accepted: 07/04/2019] [Indexed: 12/30/2022]
Abstract
In recent studies, we have investigated the monoamine oxidase (MAO) inhibition properties of pyrrolo[3,4-f]indole-5,7-dione and indole-5,6-dicarbonitrile derivatives. Since numerous high potency MAO inhibitors are present among these chemical classes, the present study synthesizes 44 additional derivatives in an attempt to further derive structure-activity relationships (SARs) and to establish optimal substitution patterns for MAO inhibition. The results show that, with the exception of one compound, all indole-5,6-dicarbonitrile derivatives (10) exhibit submicromolar IC50 values for the inhibition of MAO, with the most potent MAO-A inhibitor exhibiting an IC50 value of 0.006 μM while the most potent MAO-B inhibitor exhibits an IC50 value of 0.058 μM. Interestingly, an N-oxide derivative (4c) also proved to be a potent and nonspecific MAO inhibitor. With the exception of one compound, all of the pyrrolo[3,4-f]indole-5,7-diones (28) also exhibit submicromolar IC50 values for the inhibition of an MAO isoform. The most potent inhibitor exhibit an IC50 value of 0.011 μM for MAO-A. This study proposes that high potency MAO inhibitors such as those investigated here, may act as lead compounds for the development of treatments for neurodegenerative and neuropsychiatric disorders such as Parkinson's disease and depression.
Collapse
Affiliation(s)
| | | | | | - Igor G Abramov
- Yaroslavl State Technical University, Yaroslavl, Russian Federation
| | - Anél Petzer
- Pharmaceutical Chemistry and Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, South Africa
| | - Rialette Hitge
- Pharmaceutical Chemistry and Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, South Africa
| | - Jacobus P Petzer
- Pharmaceutical Chemistry and Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, South Africa
| | - Kyrill Yu Suponitsky
- A.N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, Moscow, Russian Federation.,Plekhanov Russian University of Economics, Moscow, Russian Federation
| |
Collapse
|
4
|
A secret that underlies Parkinson's disease: The damaging cycle. Neurochem Int 2019; 129:104484. [PMID: 31173779 DOI: 10.1016/j.neuint.2019.104484] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2019] [Revised: 05/30/2019] [Accepted: 06/03/2019] [Indexed: 01/21/2023]
Abstract
Parkinson's disease (PD) is a movement disorder, and its common characteristics include the loss of dopaminergic neurons and the accumulation of a special type of cytoplasmic inclusions called Lewy bodies in the substantia nigra pars compacta, which are more prevalent in the elderly. However, the pathophysiology of PD is still elusive. In this review, we summarized five common factors involved in PD, namely, (i) oxidative stress, (ii) mitochondrial dysfunction, (iii) inflammation, (iv) abnormal α-synuclein, and (v) endogenous neurotoxins, and proposed a hypothesis involving a damaging cycle. Oxidative stress-triggered aldehydes react with biogenic amines to produce endogenous neurotoxins. They cause mitochondrial dysfunction and the formation of inflammasomes, which induce the activation of neuroglial cells and the infiltration of T lymphocytes. The synergistic effect of these processes fosters chronic inflammation and α-synuclein aggregation and further exacerbates the impact of oxidative stress to establish a damaging cycle that eventually results in the degeneration of dopaminergic neurons. This damaging cycle provides an explanation of progressive neuronal death during the pathogenesis of PD and provides new potential targets beneficial for developing new drugs and approaches for clinical neuroprotection.
Collapse
|
5
|
Wimalasena K. Current Status, Gaps, and Weaknesses of the Mechanism of Selective Dopaminergic Toxicity of MPTP/MPP +. ADVANCES IN MOLECULAR TOXICOLOGY 2017. [DOI: 10.1016/b978-0-12-812522-9.00003-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
6
|
Kang JH. Oxidative Modification of Cytochrome c by Tetrahydropapaveroline, an Isoquinoline-Derived Neurotoxin. B KOREAN CHEM SOC 2013. [DOI: 10.5012/bkcs.2013.34.2.406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
7
|
Kyeong IG, Eum WS, Choi SY, Kang JH. Oxidative modification of neurofilament-L and neuronal cell death induced by the catechol neurotoxin, tetrahydropapaveroline. Toxicol Lett 2012; 217:59-66. [PMID: 23228886 DOI: 10.1016/j.toxlet.2012.11.029] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2012] [Revised: 11/29/2012] [Accepted: 11/29/2012] [Indexed: 11/20/2022]
Abstract
Tetrahydropapaveroline (THP), which is an endogenous neurotoxin, has been suspected to be associated with dopaminergic neurotoxicity of l-DOPA. In this study, we examined oxidative modification of neurofilament-L (NF-L) and neuronal cell death induced by THP. When disassembled NF-L was incubated with THP, protein aggregation was increased in a time- and THP dose-dependent manner. The formation of carbonyl compounds and dityrosine were observed in the THP-mediated NF-L aggregates. Radical scavengers reduced THP-mediated NF-L modification. These results suggest that the modification of NF-L by THP may be due to oxidative damage resulting from the generation of reactive oxygen species (ROS). When THP exposed NF-L was subjected to amino acid analysis, glutamate, proline and lysine residues were found to be particularly sensitive. We also investigated the effects of copper ions on THP-mediated NF-L modification. At a low concentration of THP, copper ions enhanced the modification of NF-L. Treatment of C6 astrocyte cells with THP led to a concentration-dependent reduction in cell viability. When these cells were treated with 100μM THP, the levels of ROS increased 3.5-fold compared with control cells. Furthermore, treatment of cells with THP increased NF-L aggregate formation, suggesting the involvement of NF-L modification in THP-induced cell damage.
Collapse
Affiliation(s)
- Inn Goo Kyeong
- Department of Genetic Engineering, Cheongju University, Cheongju 360-764, South Korea
| | | | | | | |
Collapse
|
8
|
Soto-Otero R, Méndez-Álvarez E, Sánchez-Iglesias S, Labandeira-García JL, Rodríguez-Pallares J, Zubkov FI, Zaytsev VP, Voskressensky LG, Varlamov AV, de Candia M, Fiorella F, Altomare C. 2-Benzazepine Nitrones Protect Dopaminergic Neurons against 6-Hydroxydopamine-Induced Oxidative Toxicity. Arch Pharm (Weinheim) 2012; 345:598-609. [DOI: 10.1002/ardp.201200007] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2012] [Revised: 03/08/2012] [Accepted: 03/09/2012] [Indexed: 01/27/2023]
|
9
|
Kyeong IG, Kang JH. Protective Effects of Carnosine and Anserine on Oxidative Modification of Neurofilament-L Induced by Catechol Neurotoxin, Tetrahydropapaveroline. B KOREAN CHEM SOC 2012. [DOI: 10.5012/bkcs.2012.33.2.731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
10
|
Kang JH. Oxidative Modification of Neurofilament-L Induced by Endogenous Neurotoxin, Salsolinol. B KOREAN CHEM SOC 2011. [DOI: 10.5012/bkcs.2011.32.9.3421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
11
|
Charron G, Doudnikoff E, Laux A, Berthet A, Porras G, Canron MH, Barroso-Chinea P, Li Q, Qin C, Nosten-Bertrand M, Giros B, Delalande F, Van Dorsselaer A, Vital A, Goumon Y, Bezard E. Endogenous morphine-like compound immunoreactivity increases in parkinsonism. Brain 2011; 134:2321-38. [PMID: 21742735 DOI: 10.1093/brain/awr166] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Morphine is endogenously synthesized in the central nervous system and endogenous dopamine is thought to be necessary for endogenous morphine formation. As Parkinson's disease results from the loss of dopamine and is associated with central pain, we considered how endogenous morphine is regulated in the untreated and l-DOPA-treated parkinsonian brain. However, as the cellular origin and overall distribution of endogenous morphine remains obscure in the pathological adult brain, we first characterized the distribution of endogenous morphine-like compound immunoreactive cells in the rat striatum. We then studied changes in the endogenous morphine-like compound immunoreactivity of medium spiny neurons in normal, Parkinson's disease-like and l-DOPA-treated Parkinson's disease-like conditions in experimental (rat and monkey) and human Parkinson's disease. Our results reveal an unexpected dramatic upregulation of neuronal endogenous morphine-like compound immunoreactivity and levels in experimental and human Parkinson's disease, only partially normalized by l-DOPA treatment. Our data suggest that endogenous morphine formation is more complex than originally proposed and that the parkinsonian brain experiences a dramatic upregulation of endogenous morphine immunoreactivity. The functional consequences of such endogenous morphine upregulation are as yet unknown, but based upon the current knowledge of morphine signalling, we hypothesize that it is involved in fatigue, depression and pain symptoms experienced by patients with Parkinson's disease.
Collapse
Affiliation(s)
- Giselle Charron
- University of Bordeaux, Institut des Maladies Neurodegeneratives, Bordeaux, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Surh YJ, Kim HJ. Neurotoxic effects of tetrahydroisoquinolines and underlying mechanisms. Exp Neurobiol 2010; 19:63-70. [PMID: 22110343 PMCID: PMC3214777 DOI: 10.5607/en.2010.19.2.63] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2010] [Accepted: 06/29/2010] [Indexed: 11/22/2022] Open
Abstract
Tetrahydropapaveroline (THP), a neurotoxic tetrahydroisoquinoline alkaloid formed by condensation between dopamine and dopaldehyde, has been speculated to cause Parkinson's disease and also to contribute to alcohol dependence. Having two catechol moieties, THP may readily undergo oxidation to form an o-quinone intermediate with concomitant production of reactive oxygen species, which can cause neuronal cell death and DNA damage. This review will deal with the current knowledge of neurotoxic effects of this endogenous alkaloid and underlying biochemical mechanisms.
Collapse
Affiliation(s)
- Young-Joon Surh
- College of Pharmacy, Seoul National University, Seoul 151-742, Korea
| | | |
Collapse
|
13
|
Kang JH. Salsolinol, a catechol neurotoxin, induces modification of ferritin: Protection by histidine dipeptide. ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY 2010; 29:246-251. [PMID: 21787609 DOI: 10.1016/j.etap.2010.01.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/26/2009] [Revised: 01/22/2010] [Accepted: 01/26/2010] [Indexed: 05/31/2023]
Abstract
1-Methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (salsolinol), an endogenous neurotoxin present in the mammalian brain, is known to perform a role in the pathogenesis of Parkinson's disease. In this study, we evaluated oxidative modifications of ferritin occurring after incubation with salsolinol. When ferritin was incubated with salsolinol, protein aggregation increased in a time-dependent manner. Free radical scavengers inhibited this salsolinol-mediated ferritin modification. The exposure of ferritin to salsolinol also results in the generation of protein carbonyl compounds and the formation of dityrosine. The results of this study show that free radicals may perform a pivotal role in salsolinol-mediated ferritin modification. Histidine dipeptides, such as carnosine, have been proposed to function as antioxidant agents in vivo. In this study, we also attempted to determine whether the histidine dipeptides, carnosine and N-acetyl-carnosine, could prevent salsolinol-mediated oxidative modification of ferritin. Our results showed that both carnosine and N-acetyl-carnosine significantly reduced ferritin aggregation. Both compounds effectively inhibited the formation of both carbonyl compounds and dityrosine. These results suggest that carnosine derivatives can, indeed, protect against salsolinol-mediated ferritin modification, as the consequence of free radical-scavenging activity.
Collapse
Affiliation(s)
- Jung Hoon Kang
- Department of Genetic Engineering, Cheongju University, Cheongju 360-764, Republic of Korea
| |
Collapse
|
14
|
Seppet E, Gruno M, Peetsalu A, Gizatullina Z, Nguyen HP, Vielhaber S, Wussling MH, Trumbeckaite S, Arandarcikaite O, Jerzembeck D, Sonnabend M, Jegorov K, Zierz S, Striggow F, Gellerich FN. Mitochondria and energetic depression in cell pathophysiology. Int J Mol Sci 2009; 10:2252-2303. [PMID: 19564950 PMCID: PMC2695278 DOI: 10.3390/ijms10052252] [Citation(s) in RCA: 62] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2009] [Revised: 04/25/2009] [Accepted: 05/14/2009] [Indexed: 12/21/2022] Open
Abstract
Mitochondrial dysfunction is a hallmark of almost all diseases. Acquired or inherited mutations of the mitochondrial genome DNA may give rise to mitochondrial diseases. Another class of disorders, in which mitochondrial impairments are initiated by extramitochondrial factors, includes neurodegenerative diseases and syndromes resulting from typical pathological processes, such as hypoxia/ischemia, inflammation, intoxications, and carcinogenesis. Both classes of diseases lead to cellular energetic depression (CED), which is characterized by decreased cytosolic phosphorylation potential that suppresses the cell's ability to do work and control the intracellular Ca(2+) homeostasis and its redox state. If progressing, CED leads to cell death, whose type is linked to the functional status of the mitochondria. In the case of limited deterioration, when some amounts of ATP can still be generated due to oxidative phosphorylation (OXPHOS), mitochondria launch the apoptotic cell death program by release of cytochrome c. Following pronounced CED, cytoplasmic ATP levels fall below the thresholds required for processing the ATP-dependent apoptotic cascade and the cell dies from necrosis. Both types of death can be grouped together as a mitochondrial cell death (MCD). However, there exist multiple adaptive reactions aimed at protecting cells against CED. In this context, a metabolic shift characterized by suppression of OXPHOS combined with activation of aerobic glycolysis as the main pathway for ATP synthesis (Warburg effect) is of central importance. Whereas this type of adaptation is sufficiently effective to avoid CED and to control the cellular redox state, thereby ensuring the cell survival, it also favors the avoidance of apoptotic cell death. This scenario may underlie uncontrolled cellular proliferation and growth, eventually resulting in carcinogenesis.
Collapse
Affiliation(s)
- Enn Seppet
- Department of Pathophysiology, University of Tartu, Tartu, Estonia; E-Mail:
(M.G.)
| | - Marju Gruno
- Department of Pathophysiology, University of Tartu, Tartu, Estonia; E-Mail:
(M.G.)
| | - Ants Peetsalu
- Department of Surgery, University of Tartu, Tartu, Estonia; E-Mail:
(A.P.)
| | - Zemfira Gizatullina
- KeyNeurotek AG, ZENIT-Technology Park Magdeburg, Magdeburg, Germany; E-Mails:
(Z.G.);
(D.J.);
(M.S.);
(K.J.);
(F.S.);
(F.N.G.)
| | - Huu Phuc Nguyen
- Department of Medical Genetics, University of Tübingen, Tübingen, Germany; E-Mail:
(H.P.N.)
| | - Stefan Vielhaber
- Department of Neurology, Otto von Guericke University, Magdeburg, Germany; E-Mail:
(S.V.)
| | - Manfred H.P. Wussling
- Bernstein Institute for Physiology, Martin-Luther-University Halle-Wittenberg, Germany; E-Mail:
(M.H.P.W.)
| | - Sonata Trumbeckaite
- Institute for Biomedical Research, Kaunas University of Medicine, Kaunas, Lithuania; E-Mails:
(S.T.);
(O.A.)
| | - Odeta Arandarcikaite
- Institute for Biomedical Research, Kaunas University of Medicine, Kaunas, Lithuania; E-Mails:
(S.T.);
(O.A.)
| | - Doreen Jerzembeck
- KeyNeurotek AG, ZENIT-Technology Park Magdeburg, Magdeburg, Germany; E-Mails:
(Z.G.);
(D.J.);
(M.S.);
(K.J.);
(F.S.);
(F.N.G.)
| | - Maria Sonnabend
- KeyNeurotek AG, ZENIT-Technology Park Magdeburg, Magdeburg, Germany; E-Mails:
(Z.G.);
(D.J.);
(M.S.);
(K.J.);
(F.S.);
(F.N.G.)
| | - Katharina Jegorov
- KeyNeurotek AG, ZENIT-Technology Park Magdeburg, Magdeburg, Germany; E-Mails:
(Z.G.);
(D.J.);
(M.S.);
(K.J.);
(F.S.);
(F.N.G.)
| | - Stephan Zierz
- Department of Neurology, Martin-Luther-University Halle-Wittenberg, Germany; E-Mail:
(S.Z.)
| | - Frank Striggow
- KeyNeurotek AG, ZENIT-Technology Park Magdeburg, Magdeburg, Germany; E-Mails:
(Z.G.);
(D.J.);
(M.S.);
(K.J.);
(F.S.);
(F.N.G.)
| | - Frank N. Gellerich
- KeyNeurotek AG, ZENIT-Technology Park Magdeburg, Magdeburg, Germany; E-Mails:
(Z.G.);
(D.J.);
(M.S.);
(K.J.);
(F.S.);
(F.N.G.)
| |
Collapse
|
15
|
Soto-Otero R, Méndez-Álvarez E, Sánchez-Iglesias S, Zubkov FI, Voskressensky LG, Varlamov AV, de Candia M, Altomare C. Inhibition of 6-hydroxydopamine-induced oxidative damage by 4,5-dihydro-3H-2-benzazepine N-oxides. Biochem Pharmacol 2008; 75:1526-37. [DOI: 10.1016/j.bcp.2007.12.010] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2007] [Revised: 12/27/2007] [Accepted: 12/31/2007] [Indexed: 11/29/2022]
|